High Response Rates With T-DXd in Early HER2-Low Breast Cancer

"The study provides a rich platform for additional translational research to evaluate more sensitive methods of HER2 detection."

Related Keywords

Boston ,Massachusetts ,United States ,Houston ,Texas ,San Antonio ,Jasona Mouabbi ,Aditya Bardia ,Daiichi Sankyo ,Eli Lilly ,Fresenius Kabi ,Genentech ,University Of Texas Md Anderson Cancer Center ,Hospital Cancer Center ,Translational Research In Oncology ,Novartis ,Pfizer ,Napo Pharmaceuticals ,Astrazeneca ,Cardinal Health ,Radius Health ,Immunomedics Gilead Sciences ,Massachusetts General Hospital Cancer Center ,Antonio Breast Cancer ,Cancer Center ,Gilead Sciences ,Breast Cancer ,Alignant Breast Neoplasm ,Biologic Therapy ,Cancer ,Alignant Neoplasia ,Arcinoma ,Antineoplastic Drug ,Nti Cancer Agents ,Evacizumab ,Rlotinib ,Efitinib ,Matinib ,Ituximab ,U11248 ,Unitinib ,Rastuzumab ,Toxicology ,Breast ,Tumor ,Translational Research ,Ranslative Research ,Translational Science ,Antigens ,Chemotherapy ,Humanized Monoclonal Antibody ,Neoa ,